The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2016

Filed:

Nov. 16, 2012
Applicant:

The Administrators of the Tulane Educational Fund, New Orleans, LA (US);

Inventors:

Vecihi Batuman, New Orleans, LA (US);

Jerome L. Maderdrut, New Orleans, LA (US);

Min Li, New Orleans, LA (US);

David H. Coy, New Orleans, LA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/22 (2006.01); A61P 13/02 (2006.01); C07K 14/575 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 14/57563 (2013.01); A61K 38/2242 (2013.01); A61K 38/2278 (2013.01); A61K 45/06 (2013.01);
Abstract

Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.


Find Patent Forward Citations

Loading…